Advertisement

Kallikrein-Kinin- und Prostaglandin-Systeme bei Hypertonie

  • J. M. Sullivan
  • J. C. McGiff

Zusammenfassung

Der Beginn mancher Formen von Hypertonie sowie die Entwicklung der akzelerierten Phase der essentiellen Hypertonie spiegelt das Wirken eines oder mehrer hormonaler Pressorfaktoren wider, wie z. B. gesteigerte Aktivität des Renin-Angiotensin-Systems oder Mineralokortikoidüberschuß. Von nicht geringerer Bedeutung für die Blutdruckregulation ist das Versagen von Gegenkräften, die normalerweise eine Senkung des Blutdrucks bewirken. Das Kallikrein-Kinin-System besitzt die erforderlichen Eigenschaften, diese Funktion wahrzunehmen, insbesondere wenn man es unter dem Aspekt seiner Wechselwirkung mit Prostaglandinen betrachtet [84] (Abb. 1). Ein Ausbleiben der normalen Ausgleichsfunktion kann eine anhaltende Hypertonie verursachen ohne Aktivitätszunahme irgendeines Pressorfaktors. So kann, wenn man von der tonischen Aktivität entgegenwirkender Blutdruckregulationssysteme ausgeht, eine Dysfunktion im Vasodepressorsystem zu Hypertonie führen, ohne daß eine Zunahme der Grundaktivität des blutdruckerhöhenden Systems erfolgt. Innerhalb der Niere, und wahrscheinlich auch in den extrarenalen Blutgefäßen, stehen Prostaglandine in Wechselwirkung mit den hauptsächlichen Blutdruckregulationssystemen, dem Kallikrein-Kinin-System und dem adrenerg inner-vierten Renin-Angiotensin-System, unter Verstärkung des ersteren und Pufferung des letzteren [143]. Damit tragen Prostaglandine zur blutdrucksenkenden Wirkung der Kinine bei und machen die blutdruckerhöhende Wirkung von Angiotensinen zunichte. Eine verminderte Reaktionsfähigkeit des renalen Kallikreinsystems zeigte sich bei einigen Formen von Hypertonie beim Menschen und im Experiment [63, 79].

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  1. 1.
    Ahnfelt-Ronne I, Arrigoni-Martelli E (1978) Increased PGF2a synthesis in renal papilla of spontaneously hypertensive rats. Biochem Pharmacol 27: 2363–2367CrossRefPubMedGoogle Scholar
  2. 2.
    Aiken JW (1974) Effects of prostaglandin synthesis inhibitors on angiotensin tachyphylaxis in the isolated coeliac and mesenteric arteries of the rabbit. Pol J Pharmacol Pharm 26: 217–227CrossRefPubMedGoogle Scholar
  3. 3.
    Aiken JW, Vane JR (1973) Intrarenal prostaglandin release attenuates the renal vasoconstrictor activity of angiotensin. J Pharmacol Exp Ther 183: 678–687Google Scholar
  4. 4.
    Armstrong JM, Lattimer N, Moncada S, Vane JR (1978) Comparison of the vasodepressor effects of prostacyclin and 6-oxo-prostaglandinF,a with those of prostaglandin E2 in rats and rabbits. Br J Pharmacol 62: 125–130CrossRefPubMedGoogle Scholar
  5. 5.
    Baer PG, Cagen LM (1981) Renal prostaglandin excretion and metabolism in male and female New Zealand normotensive and genetically hypertensive rats. Hypertension 3: 257–261CrossRefPubMedGoogle Scholar
  6. 6.
    Bartter FC, Pronove P, Gill JR Jr, MacCardle RC (1962) Hyperplasia of the juxtaglomerular complex with hyperaldosteronism and hypokalemic alkalosis. A new syndrome. Am J Med 33: 811–828Google Scholar
  7. 7.
    Bayliss WM (1902) On the local reaction of the arterial wall to changes in internal pressure. J Physiol 28: 220–231PubMedGoogle Scholar
  8. 8.
    Beaty O III, Donald DE (1979) Contribution of prostaglandins to muscle blood flow in anesthetized dogs at rest, during exercise, and following inflow occlusion. Circ Res 44: 67–75CrossRefPubMedGoogle Scholar
  9. 9.
    Beilin LJ, Bhattacharya J (1977) The effect of prostaglandin synthesis inhibitors on renal blood flow distribution in conscious rabbits. J Physiol 269: 395–405PubMedGoogle Scholar
  10. 10.
    Benzoni D, Vincent M, Sassard J (1982) Urinary prostaglandins in the Lyon strains of hypertensive, normotensive, and low blood pressure rats. Hypertension 4: 325–328CrossRefPubMedGoogle Scholar
  11. 11.
    Berl T, Raz A, Wald H, Horowitz J, Czaczkes W (1977) Prostaglandin synthesis inhibition and the action of vasopressin: studies in man and rat. Am J Physiol 323 (6): F529 - F537Google Scholar
  12. 12.
    Bevan VH, Pierce JV, Pisano JJ (1971) A sensitive isotopic procedure for the assay of esterase activity: measurement of human urinary kallikrein. Clin Chem Acta 32: 67–73CrossRefGoogle Scholar
  13. 13.
    Bunting S, Gryglewski R, Moncada S, Vane JR (1976) Arterial walls generate from prostaglandin endoperoxides a substance (prostaglandin X) which relaxes strips of mesenteric and coeliac arteries and inhibits platelet aggregation. Prostaglandins 12: 897–915PubMedGoogle Scholar
  14. 14.
    Campbell WB, Holland OB, Adams BV, Gomez-Sanchez CE (1982) Urinary excretion of prostaglandin E2, prostaglandin F2a, and thromboxane B2 in normotensive and hypertensive subjects on varying sodium intakes. Hypertension 4: 735–741CrossRefPubMedGoogle Scholar
  15. 15.
    Carone FA, Pullman TN, Oparil S, Nakamura S (1976) Micropuncture evidence of rapid hydrolysis of bradykinin by rat proximal tubule. Am J Physiol 230: 1420–1424PubMedGoogle Scholar
  16. 16.
    Carr AA (1970) Hemodynamic and renal effects of a prostaglandin, PGA(1) in subjects with essential hypertension. Am J Med Sci 259: 21–26CrossRefPubMedGoogle Scholar
  17. 17.
    Carretero OA, Scicli AG (1976) Renal kallikrein: its localization and possible role in renal function. Fed Proc 35: 194–198PubMedGoogle Scholar
  18. 18.
    Chaignon M, Ruffle ML, Lucsko M, Cuche JL, Guedon J (1982) Prostacyclin infusion in hypertension: Acute hemodynamic and hormonal effects. N Engl J Med 307: 559Google Scholar
  19. 19.
    Chrysant SG, Townsend SM, Morgan PR (1978) The effects of salt and meclofenamate administration on the hypertension of spontaneously hypertensive rats. Clin Exp Hypertension 1: 381–391CrossRefGoogle Scholar
  20. 20.
    Coleman RW (1974) Formation of human plasma kinin. N Engl J Med 291: 509–515CrossRefGoogle Scholar
  21. 21.
    Colina-Chourio J, McGiff JC, Miller MP, Nasjletti A (1976) Possible influence of intrarenal generation of kinins on prostaglandin release from the rabbit perfused kidney. Br J Pharmacol 58: 165–172CrossRefPubMedGoogle Scholar
  22. 22.
    Colina-Chourio J, McGiff JC, Nasjletti A (1979) Effect of indomethacin on blood pressure in the normotensive unanesthetized rabbit: Possible relation to prostaglandin synthesis inhibition. Clin Sci 57: 359–365Google Scholar
  23. 23.
    Damas J, Bourdon V (1974) Libération d’acide arachidonique par la bradykinine. Comptes Rendus des Séances de la Société de Biologie et de Ses Filiales 168: 1445–1448PubMedGoogle Scholar
  24. 24.
    DeJong PE, Donker MM, Van der Wall E, Erkelens DW, Van der Hem GK, Doorenbos H (1980) Effect of indomethacin in two siblings with a renin-dependent hypertension, hyperaldosteronism and hypokalemia. Nephron 25: 47–52CrossRefGoogle Scholar
  25. 25.
    DuCharme DW, Weeks JR, Montgomery RC (1968) Studies on the mechanism of the hypertensive effect of prostaglandin F2a. J Pharmacol Exp Ther 160: 1–10PubMedGoogle Scholar
  26. 26.
    Dunn MJ (1976) Renal prostaglandin synthesis in the spontaneously hypertensive rat. J Clin Invest 58: 862–870CrossRefPubMedGoogle Scholar
  27. 27.
    Durâo V, Prata MM, Gonçalves LMP (1977) Modification of antihypertensive effect of /3adrenoceptor-blocking agents by inhibition of endogenous prostaglandin synthesis. Lancet 2: 1005–1007CrossRefPubMedGoogle Scholar
  28. 28.
    Dusting GJ, Moncada S, Vane JR (1978) Recirculation of prostacyclin (PGI2) in the dog. Br J Pharmacol 64: 315–320CrossRefPubMedGoogle Scholar
  29. 29.
    Elliot AH, Nuzum FR (1934) Urinary excretion of a depressor substance (kallikrein of Frey and Kraut) in arterial hypertension. Endocrinology 18: 462–474CrossRefGoogle Scholar
  30. 30.
    Ellis EF, Oelz O, Roberts LJ, Payne NA, Sweet-man BJ, Nies AS, Oates JA (1976) Coronary arterial smooth muscle contraction by a substance released from platelets: evidence that it is thromboxane A2. Science 193: 1135–1137CrossRefPubMedGoogle Scholar
  31. 31.
    Erdös EG (1975) Angiotensin I converting enzyme. Circ Res 36: 247–255CrossRefPubMedGoogle Scholar
  32. 32.
    Erdös EG (1976) The kinins. A status report. Biochem Pharmacol 25: 1563–1569CrossRefPubMedGoogle Scholar
  33. 33.
    Folkow B, Neil E (1971) The Principles of Vascular Control. In: Folkow B, Neil E (eds) Circulation. Oxford University Press, New York, pp 285–306Google Scholar
  34. 34.
    Frölich JC, Sweetman BJ, Can K, Hollifield JW, Oates JA (1975) Assessment of the levels of PGA2 in human plasma by gas chromatography mass spectrometry. Prostaglandins 10: 185–195PubMedGoogle Scholar
  35. 35.
    Frölich JC, Hollifield JW, Dormois JC, Frölich BL, Seyberth H, Michelakis AM, Oates JA (1976) Suppression of plasma renin activity by indomethacin in man. Circ Res 39: 447–452CrossRefPubMedGoogle Scholar
  36. 36.
    Frölich JC, Hollifield JW, Oates JA (1976) Reduction of plasma renin activity by inhibition of cyclo-oxygenase: independence of sodium retention. Clin Res 24: 271AGoogle Scholar
  37. 37.
    Galvez OG, Bay WH, Roberts BW, Ferris TF 276 J. M. Sullivan und J. C. McGiff (1977) The hemodynamic effects of potassium deficiency in the dog. Circ Res 40: I-11-I-16Google Scholar
  38. 38.
    Gerber JG, Nies AS (1979) The hemodynamic effects of prostaglandins in the rat. Evidence for important species variation in renovascular responses. Circ Res 44: 406–410Google Scholar
  39. 39.
    Gill JR, Frölich JC, Bowden RE, Taylor AA, Keiser HR, Seyberth HW, Oates JA, Bartter FC (1976) Bartter’s syndrome: a disorder characterized by high urinary prostaglandins and a dependence of hyperreninemia on prostaglandin synthesis. Am J Med 61: 43–51CrossRefPubMedGoogle Scholar
  40. 40.
    Gimeno MF, Sterin-Borda L, Borda ES, Lazzari MA, Gimeno AL (1980) Human plasma transforms prostacyclin (PGI2) into a platelet antiaggregatory substance which contracts isolated bovine coronary arteries. Prostaglandins 19: 907–916PubMedGoogle Scholar
  41. 41.
    Granström E (1977) Metabolism of prostaglandins. In: Berti F, Samuelsson B, Velo GP (eds) Prostaglandins and Thromboxanes. Plenum Press, New York, pp 75–83CrossRefGoogle Scholar
  42. 42.
    Grantham JJ, Orloff J (1968) Effect of prostaglandin E1 on the permeability response of the isolated collecting tubule to vasopressin, adenosine 3’, 5’-monophosphate, and theophylline. J Clin Invest 47: 1154–1161CrossRefPubMedGoogle Scholar
  43. 43.
    Grodzinska L, Gryglewski RJ (1980) Angiotensin-induced release of prostacyclin from per-fused organs. Pharmac Res Commun 12: 339–347CrossRefGoogle Scholar
  44. 44.
    Gryglewski RJ, Korbut R, Ocetkiewicz A (1978) Generation of prostacyclin by lungs in vivo and its release into the arterial circulation. Nature 273: 765–767CrossRefPubMedGoogle Scholar
  45. 45.
    Guyton AC, Coleman TG, Cowley AW Jr, Manning RD Jr, Norman RA Jr, Ferguson JD (1974) A systems analysis approach to understanding long-range arterial blood pressure control and hypertension. Circ Res 35: 159–176CrossRefGoogle Scholar
  46. 46.
    Halushka PV, Wohltmann H, Privitera PJ, Hurwitz G, Margolius HS (1977) Bartter’s syndrome: urinary prostaglandin E-like material and kallikrein; indomethacin effects. Ann Intern Med 87: 281–286PubMedGoogle Scholar
  47. 47.
    Hamberg M, Samuelsson B (1974) Prostaglandin endoperoxides. Novel transformations of arachidonic acid in human platelets. Proc Natl Acad Sci USA 71: 3400–3404Google Scholar
  48. 48.
    Hamberg M, Svensson J, Samuelsson B (1975) Thromboxanes: a new group of biologically active compounds derived from prostaglandin endoperoxides. Proc Natl Acad Sci USA 72: 2994–2998CrossRefPubMedGoogle Scholar
  49. 49.
    Hedqvist P (1970) Studies on the effect of prostaglandins E1 and E2 on the sympathetic neuromuscular transmission in some animal tissues. Acta Physiol Scand (Suppl) 345: 1–40Google Scholar
  50. 50.
    Hensby CN, Dollery CT, Barnes PJ, Dargie H (1979) Production of 6-oxo-PGF1a by human lung in vivo. Lancet 2: 1162–1163CrossRefPubMedGoogle Scholar
  51. 51.
    Hollenberg NK, Solomon HS, Adams DF, Abrams HL, Merrill JP (1972) Renal vascular responses to angiotensin and norepinephrine in normal man. Circ Res 31: 750–757CrossRefPubMedGoogle Scholar
  52. 52.
    Hong SL, Levine L (1976) Stimulation of prostaglandin synthesis by bradykinin and thrombin and their mechanisms of action on MC5–5 fibroblasts. J Biol Chem 251: 5814–5816PubMedGoogle Scholar
  53. 53.
    Hoult JR, Moore PK (1977) Pathways of prostaglandin Fla metabolism in mammalian kidneys. Br J Pharmacol 61: 615–626CrossRefPubMedGoogle Scholar
  54. 54.
    Hoult JRS, Lofts FJ, Moore PK (1981) Stability of prostacyclin in plasma and its transformation by platelets to a stable spasmogenic product. Proc Br J Pharmacol Soc 68 (abstract)Google Scholar
  55. 55.
    Hulthén UL, Lecerof H, Hökfelt B (1977) Renal venous output of kinins in patients with hypertension and unilateral renal artery stenosis. Acta Med Scand 202: 189–191CrossRefPubMedGoogle Scholar
  56. 56.
    Ishii M, Uehara Y, Hirata Y, Atarashi K, Ikeda T, Susimoto T, Takeda T, Murao S (1982) Effects of norepinephrine infusion on systemic hemodynamics and plasma 6-keto-prostaglandin Fla in normotensive subjects and patients with essential hypertension. Jpn Circ J 46 (5): 494–502CrossRefPubMedGoogle Scholar
  57. 57.
    Itskovitz HD, McGiff JC (1974) Hormonal regulation of the renal circulation. Circ Res 34 (Supp11): 65–73Google Scholar
  58. 58.
    Itskovitz HD, Terragno NA, McGiff JC (1974) Effect of a renal prostaglandin on distribution of blood flow in the isolated canine kidney. Circ Res 34: 770–776CrossRefPubMedGoogle Scholar
  59. 59.
    Jackson EK, Herzer WA, Zimmerman JB, Branch RA, Oates JA, Gerkens JF (1981) 6-ketoprostaglandin E1 is more potent than prostaglandin I2 as a renal vasodilator and renin secretagogue. J Pharmacol Exper Ther 216: 24–27Google Scholar
  60. 60.
    Jackson EK, Heideman HT, Branch RA, Ger-kens JF (1982) Low dose intrarenal infusions of PGE2, PGI2, and 6-keto-PGF, vasodilate the in vivo rat kidney. Circ Res 51: 67–72CrossRefPubMedGoogle Scholar
  61. 61.
    Janszen FHA, Nugteren DH (1971) Histochemical localisation of prostaglandin synthetase. Histochemie 27: 159–164CrossRefPubMedGoogle Scholar
  62. 62.
    Keiser HR, Andrews MJ Jr, Guyton RA, Margolius HS, Pisano JJ (1976) Urinary kallikrein in dogs with constriction of one renal artery. Proc Soc Exp Biol Med 151: 53–56PubMedGoogle Scholar
  63. 63.
    Keiser HR, Geller RG, Margolius HS, Pisano JJ (1976) Urinary kallikrein in hypertensive animal models. Fed Proc 35: 199–202PubMedGoogle Scholar
  64. 64.
    Larsson C, Änggard E (1973) Regional differences in the formation and metabolism of prostaglandins in the rabbit kidney. Eur J Pharmacol 21: 30–36CrossRefPubMedGoogle Scholar
  65. 65.
    Larsson C, Weber P, Änggard E (1974) Arachidonic acid increases and indomethacin decreases plasma renin activity in the rabbit. Eur J Pharmacol 28: 391–394CrossRefPubMedGoogle Scholar
  66. 66.
    Lebel M, Grose JH (1982) Renal prostaglandins in borderline and sustained essential hypertension. Prostaglandins-Leukotrienes-Med 8 (5): 409–418Google Scholar
  67. 67.
    Lee JB, Crowshaw K, Takman BH, Attrep KA, Gougoutas JC (1967) Identification of prostaglandins E2, F2a and A2 from rabbit kidney medulla. Biochem J 105: 1251–1260PubMedGoogle Scholar
  68. 68.
    Levy SB, Lilley JJ, Frigon RP, Stone RA (1977) Urinary kallikrein and plasma renin activity as determinants of renal blood flow: the influence of race and dietary sodium intake. J Clin Invest 60: 129–138CrossRefPubMedGoogle Scholar
  69. 69.
    Lima DR, Turner P (1982) Beta-blocking drugs increase responsiveness to prostacyclin in hypertensive patients. Lancet 2: 444CrossRefPubMedGoogle Scholar
  70. 70.
    Limas CJ, Limas C (1977) Prostaglandin metabolism in the kidneys of spontaneously hypertensive rats. Am J Physiol 233 (1): H87 - H92PubMedGoogle Scholar
  71. 71.
    Lonigro AJ, Itskovitz HD, Crowshaw K, McGiff JC (1973) Dependency of renal blood flow on prostaglandin synthesis in the dog. Circ Res 32: 712–717CrossRefPubMedGoogle Scholar
  72. 72.
    Malik KU (1978) Prostaglandin-mediated inhibition of the vasoconstrictor responses of the isolatet perfused rat splenic vasculature to adrenergic stimuli. Circ Res 43 (2): 225–233CrossRefPubMedGoogle Scholar
  73. 73.
    Malik KU (1978) Prostaglandins–modulation of adrenergic nervous system. Fed Proc 37: 203–207PubMedGoogle Scholar
  74. 74.
    Malik KU, McGiff JC (1975) Modulation by prostaglandins of adrenergic transmission in the isolated perfused rabbit and rat kidney. Circ Res 36: 599–609CrossRefPubMedGoogle Scholar
  75. 75.
    Malik KU, McGiffJC (1976) Cardiovascular actions of prostaglandins. In: Karim SMM (ed) Prostaglandins: Physiological, pharmacological and pathological aspects. MTP Press, Lancaster, pp 103–200Google Scholar
  76. 76.
    Malmsten C, Hamberg M, Svensson J, Samuels-son B (1975) Physiological role of an endoperoxide in human platelets: hemostatic defect due to platelet cyclo-oxygenase deficiency. Proc Natl Acad Sci USA 72: 1446–1450CrossRefPubMedGoogle Scholar
  77. 77.
    Margolius HS, Geller R, de Jong W, Pisano JJ, Sjoerdsma A (1972) Altered urinary kallikrein excretion in rats with hypertension. Circ Res 30: 358–362CrossRefPubMedGoogle Scholar
  78. 78.
    Margolius HS, Horwitz D, Pisano JJ, Keiser HR (1974) Urinary kallikrein excretion in hypertensive man. Relationships to sodium intake and sodium-retaining steroids. Circ Res 35: 820–825Google Scholar
  79. 79.
    Margolius HS, Horwitz D, Pisano JJ, Keiser HR (1976) Relationships among urinary kallikrein, mineralocorticoids and human hypertensive disease. Fed Proc 35: 203–206PubMedGoogle Scholar
  80. 80.
    Marin-Grez M (1974) The influence of antibodies against bradykinin on isotonic saline diuresis in the rat. Pflügers Arch 350: 231–239CrossRefGoogle Scholar
  81. 81.
    Marin-Grez M, Cottone P, Carretero A (1972) Evidence for an involvement of kinins in regulation of sodium excretion. Am J Physiol 223: 794–796PubMedGoogle Scholar
  82. 82.
    Marin-Grez M, Schaechtelin G, Bonner G, Speck G, Ganten D, Groß F (1982) Renal kallikrein activity and urinary kallikrein excretion in rats with experimental renal hypertension. Clin Sci 63 (4): 349–354PubMedGoogle Scholar
  83. 83.
    McGiff JC (1977) Bartter’s syndrome results from an imbalance of vasoactive hormones. Ann Intern Med 87: 369–372PubMedGoogle Scholar
  84. 84.
    McGiff JC, Nasjletti A (1976) Kinins, renal function and blood pressure regulation. A symposium of the American Society for Pharmacology and Experimental Therapeutics presented at the 59th Annual Meeting of the Federation of American Societies for Experimental Biology, Atlantic City, New Jersey, 1975. ( Chairman, McGiff JC). Fed Proc 35: 172–174Google Scholar
  85. 85.
    McGiff JC, Terragno NA, Strand JC, Lee JB, Lonigro AJ, Ng KKF (1969) Selective passage of prostaglandins across the lung. Nature 223: 742–745CrossRefPubMedGoogle Scholar
  86. 86.
    McGiff JC, Crowshaw K. Terragno NA, Lonigro AJ (1970) Release of a prostaglandin-like substance into renal venous blood in response to angiotensin II. Circ Res 26–27 (Suppl 1): 121–130Google Scholar
  87. 87.
    McGiff JC, Crowshaw K, Terragno NA, Lonigro AJ (1970) Renal prostaglandins: possible regulators of the renal actions of pressor hormones. Nature 227: 1255–1257CrossRefPubMedGoogle Scholar
  88. 88.
    McGiff JC, Terragno NA, Malik KU, Lonigro AJ (1972) Release of prostaglandin E-like substance from canine kidney by bradykinin. Circ Res 31: 36–43CrossRefPubMedGoogle Scholar
  89. 89.
    McGiff JC, Itskovitz HD, Terragno NA (1975) The action of bradykinin and eledoisin in the canine isolated kidney; relationships to prostaglandins. Clin Sci Mol Med 49: 125–131PubMedGoogle Scholar
  90. 90.
    McQueen D, Bell K (1976) The effects of prostaglandin E1 and sodium meclofenamate on blood pressure in renal hypertensive rats. Eur J Pharmacol 37: 223–235CrossRefPubMedGoogle Scholar
  91. 91.
    Meneely GR, Ball COT, Youmans JB (1957) Chronic sodium chloride toxicity: the protective effect of added potassium chloride. Ann Int Med 47: 263–273PubMedGoogle Scholar
  92. 92.
    Mersey JH, Williams GH, Hollenberg NK, Dluhy RG (1977) Relationship between aldosterone and bradykinin. Circ Res 40 (Suppl 1): 184–188Google Scholar
  93. 93.
    Messina EJ, Weiner R, Kaley G (1975) Inhibition of bradykinin vasodilation and potentiation of norepinephrine and angiotensin vasoconstriction by inhibitors of prostaglandin synthesis in rat skeletal muscle. Circ Res 37: 430–437CrossRefPubMedGoogle Scholar
  94. 94.
    Mills IH, MacFarlane NAA, Ward PE, Obika LFO (1976) The renal kallikrein-kinin system and the regulation of salt and water excretion. Fed Proc 35: 181–188PubMedGoogle Scholar
  95. 95.
    Moncada S, Higgs EA, Vane JR (1977) Human arterial and venous tissues generate prostacyclinGoogle Scholar
  96. 278.
    J. M. Sullivan und J. C. McGiff (prostaglandin X), a potent inhibitor of platelet aggregation. Lancet 1: 18–20Google Scholar
  97. 96.
    Moncada S, Korbut R, Bunting S, Vane JR (1978) Prostacyclin is a circulating hormone. Nature 273: 767–768CrossRefPubMedGoogle Scholar
  98. 97.
    Morrison A, Nishikawa K, Needleman P (1977) Unmasking of thromboxane A2 synthesis by ureteral obstruction in the rabbit kidney. Nature 267: 259–260CrossRefPubMedGoogle Scholar
  99. 98.
    Muirhead EE, Leach BE, Byers LW, Brooks B, Daniels EG, Hinman JW (1971) Antihypertensive neutral renomedullary lipids (ANRL). In: Fisher JW (ed) Kidney Hormones. Academic Press, New York, pp 485–506Google Scholar
  100. 99.
    Muirhead EE, Brooks B, Brosius WL (1976) Indomethacin and blood pressure control. J Lab Clin Med 88: 578–583PubMedGoogle Scholar
  101. 100.
    Mullane KM, Moncada S (1980) Prostacyclin release and the modulation of some vasoactive hormones. Prostaglandins 20: 25–49PubMedGoogle Scholar
  102. 101.
    Nakano JM, McCurdy JR (1967) Cardiovascular effects of prostaglandin El. J Pharmacol Exp Ther 156: 538–547PubMedGoogle Scholar
  103. 102.
    Nanra RS, Chirawong P, Kincaid-Smith P (1973) Medullary ischemia in experimental analgesic nephropathy - the pathogenesis of renal papillary necrosis. Aust N. Z. Med 3: 580–586Google Scholar
  104. 103.
    Nasjletti A, Colina-Chourio J (1976) Interaction of mineralocorticoids, renal prostaglandins and the renal kallikrein-kinin system. Fed Proc 35: 189–193PubMedGoogle Scholar
  105. 104.
    Nasjletti A, Malik KU (1981) Interrelations between prostaglandins and vasoconstrictor hormones: Contribution to blood pressure regulation. Med Clin North Am 65: 881–889Google Scholar
  106. 105.
    Nasjletti A, Colina-Chourio J, McGiffJC (1975) Disappearance of bradykinin in the renal circulation of dogs. Effects of kininase inhibition. Circ Res 37: 59–65Google Scholar
  107. 106.
    Nasjletti A, McGiffJC, Colina-Chourio J (1978) Interrelationships of the renal kallikrein-kinin and prostaglandin systems in the conscious rat: Influence of mineralocorticoids. Circ Res 43: 799–807Google Scholar
  108. 107.
    Needleman P, Raz A, Ferrendelli JA, Minkes M (1977) Application of imidazole as a selective inhibitor of thromboxane synthetase in human platelets. Proc Natl Acad Sci USA 74: 1716–1720CrossRefPubMedGoogle Scholar
  109. 108.
    Negus P, Tannen RL, Dunn MJ (1976) Indomethacin potentiates the vasoconstrictor actions of angiotensin II in normal man. Prostaglandins 12: 175–180PubMedGoogle Scholar
  110. 109.
    Nowak J, Wennmalm Ä (1978) Influence of indomethacin and prostaglandin E1 on total and regional blood flow in man. Acta Physiol Scand 102: 484–491CrossRefPubMedGoogle Scholar
  111. 110.
    O’Connor DT (1982) Response of the renal kallikrein-kinin system, intravascular volume, and renal hemodynamics to sodium restriction and diuretic treatment in essential hypertension. Hypertension 4 (Suppl 3): 72–78Google Scholar
  112. 111.
    O’Connor DT (1982) Response of the renal kallikrein-kinin system, intravascular volume, and renal hemodynamics to sodium restriction and diuretic treatment in essential hypertension. Hypertension 4 (2): 172–178Google Scholar
  113. 112.
    O’Connor DT, Bars AP, Amend W, Vincenti F (1982) Urinary kallikrein excretion after renal transplantation: relationship to hypertension, graft source, and renal function. Am J Med 73 (4): 475–481CrossRefPubMedGoogle Scholar
  114. 113.
    Orstavik TB, Nustad K, Brandtzaeg P, Pierce JV (1976) Cellular origin of urinary kallikreins. J Histochem Cytochem 24: 1037–1039CrossRefGoogle Scholar
  115. 114.
    Pace-Asciak CP (1976) Decreased renal prostaglandin catabolism precedes onset of hypertension in the developing spontaneously hypertensive rat. Nature 263: 510–512CrossRefPubMedGoogle Scholar
  116. 115.
    Pace-Asciak CR, Carrara MC, Rangaraj G, Nicolaou KC (1978) Enhanced formation of PGI2, a potent hypotensive substance, by aortic rings and homogenates of the spontaneously hypertensive rat. Prostaglandins 15 (6): 1005–1012PubMedGoogle Scholar
  117. 116.
    Patak RB, Mookerjee C, Bentzel P, Hysert P, Babe M, Lee J (1975) Antagonism of the effects of furosemide by indomethacin in normal and hypertensive man. Prostaglandins 10: 649–659PubMedGoogle Scholar
  118. 117.
    Pierce JV, Webster ME (1961) Human plasma kallidins: Isolation and chemical studies. Biochem Biophys Res Commun 5: 363–357Google Scholar
  119. 118.
    Piper PJ, Vane JR (1969) Release of additional factors in anaphylaxis and its antagonism by anti-inflammatory drugs. Nature 223: 29–35CrossRefPubMedGoogle Scholar
  120. 119.
    Pipili E, Poyser NL (1982) Release of prostaglandins I2 and E2 from the perfused mesenteric arterial bed of normotensive and hypertensive rats. Effects of sympathetic nerve stimulation and norepinephrine administration. Prostaglandins 23 (4): 543–549PubMedGoogle Scholar
  121. 120.
    Pugsley DJ, Mullins R, Beilin LJ (1976) Renal prostaglandin synthesis in hypertension induced by deoxycorticosterone and sodium chloride in the rat. Clin Sci Mol Med 51 (Suppl) 3: 253s - 256sGoogle Scholar
  122. 121.
    Rathaus M, Bernheim J (1982) Effect of propranolol treatment on the urinary excretion of prostaglandins E2 and Fla in patients with essential hypertension. Isr J Med Sci 18 (2): 231–234PubMedGoogle Scholar
  123. 122.
    Rioux F, Quirion R, Regoli D (1977) The role of prostaglandins in hypertension. I. The release of prostaglandins by aorta strips of renal, DOCAsalt, and spontaneously hypertensive rats. Can J Physiol Pharmacol 55: 1330–1338Google Scholar
  124. 123.
    Romero JC, Strong JC (1977) The effect of indomethacin blockade of prostaglandin synthesis on blood pressure of normal rabbits and rabbits with renovascular hypertension. Circ Res 40: 35–41CrossRefPubMedGoogle Scholar
  125. 124.
    Ruilope L, Garcia-Robles R, Barrientos A, Bernis C, Alcazar J, Tressuerres JA, Mancheno E, Millet VG, Sancho J, Rodicio JL (1982) The role of urinary PG E2 and renin-angiotensin-aldosterone system in the pathogenesis of essential hypertension. Clin Exp Hypertension 4 (6): 989–1000CrossRefGoogle Scholar
  126. 125.
    Saruta T, Kondo K (1982) Endocrine factors in juvenile essential hypertension. Jpn J Med 21 (2): 152–154CrossRefPubMedGoogle Scholar
  127. 126.
    Sato M, Abe K, Haruyama T, Sato K, Yasujima M, Imai Y, Hiwatari M, Kasai Y, Tajima J, Itoh S, Seino M, Chiba S, Goto T, Yoshinaga K (1982) Effect of acute water loading on urinary excretion of prostaglandin E in hypertensive patients. Prostaglandins-Leukotrienes-Med 8 (5): 517–524Google Scholar
  128. 127.
    Sato M, Abe K, Haruyama T, Yasujima M, Sato K, Chiba S, Imai Y, Hiwatari M, Kasai Y, Tajima J, Itoh S, Seino M, Goto T, Yoshinaga K (1982) Effect of dietary sodium intake on the metabolism of prostaglandins in the kidney in hypertensive patients. Prostaglandins-Leukotrienes-Med 8 (3): 199–209CrossRefGoogle Scholar
  129. 128.
    Siren AL (1982) Differences in the central actions of arachidonic acid and prostaglandin Fla between spontaneously hypertensive and normotensive rats. Life Sci 30 (6): 503–513CrossRefPubMedGoogle Scholar
  130. 129.
    Speckart P, Zia P, Zipser R, Horton R (1977) The effect of sodium restriction and prostaglandin inhibition on the renin-angiotensin system in man. J Clin Endocrinol and Metab 44: 832–837CrossRefGoogle Scholar
  131. 130.
    Spokas EG, Ferreri NR, Wong PY-K, McGiff JC (1980) Effect of 6-keto-prostaglandin E1 (6keto-PGE1) on renin release from rabbit renal cortical slices. Circulation 62: III - 287 (Abstract)Google Scholar
  132. 131.
    Stein JH, Congbalay RC, Karsh DL, Osgood RW, Ferris TF (1972) The effect of bradykinin on proximal tubular sodium reabsorption in the dog. Evidence for functional nephron heterogeneity. J Clin Invest 51: 1709–1721Google Scholar
  133. 132.
    Streeten DHP, Kerr LP, Kerr CB, Prior JC, Dalakos TG (1972) Hyperbradykininism: a new orthostatic syndrome. Lancet 2: 1048–1053CrossRefPubMedGoogle Scholar
  134. 133.
    Stygles VG, Reinke DA, Rickert DE, Hook JB (1978) Increased blood pressure in the SHR is not related to a deficit in renomedullary PGE2. Experientia 15: 1025–1026CrossRefGoogle Scholar
  135. 134.
    Sullivan JM, Patrick DR (1981) Release of prostaglandin I2-like activity from the rat aorta: Effect of captopril, furosemide and sodium. Prostaglandins 22: 575–585Google Scholar
  136. 135.
    Szczeklik A, Gryglewski RJ, Nizankowska E, Nizankowski R, Musial J (1978) Pulmonary and antiplatelet effects of intravenous and inhaled prostacyclin in man. Prostaglandins 16: 651–659Google Scholar
  137. 136.
    Tan SY, Sweet P, Mulrow PJ (1978) Impaired renal production of prostaglandin E2: a newly identified lesion in human essential hypertension. Prostaglandins 15 (1): 139–150PubMedGoogle Scholar
  138. 137.
    Terragno NA, Terragno DA, Pacholczyk D, McGiff JC (1974) Prostaglandins and the regulation of uterine blood flow in pregnancy. Nature 249: 57–58CrossRefPubMedGoogle Scholar
  139. 138.
    Terragno DA, Crowshaw K, Terragno NA, McGiff JC (1975) Prostaglandin synthesis by bovine mesenteric arteries and veins. Circ Res (Suppl 1)36–37: I76–80Google Scholar
  140. 139.
    Terragno NA, Terragno DA, McGiff JC (1977) Contribution of prostaglandins to the renal circulation in conscious, anesthetized and laparotomized dogs. Circ Res 40: 590–595CrossRefPubMedGoogle Scholar
  141. 140.
    Terragno NA, McGiff JC, Terragno A (1978) Synthesis of prostaglandin by vascular and non-vascular renal tissues and the presence of an endogenous prostaglandin synthesis inhibitor in the cortex. In: Vargaftig BB (ed) Advances in Pharmacology and Therapeutics, Volume 4, Prostaglandins and Immunopharmacology, Pergamon Press, Oxford, pp 39–46Google Scholar
  142. 141.
    Tobian L, Ganguli M, Johnson MA, Iwai J (1982) Influence of renal prostaglandins and dietary lineoleate on hypertension in Dahl S rats. Hypertension 4 (Suppl 2): II149-II 153Google Scholar
  143. 142.
    Vane JR (1969) The release and fate of vasoactive hormones in the circulation. Br J Pharmacol 35: 209–242CrossRefPubMedGoogle Scholar
  144. 143.
    Vane JR, McGiff JC (1975) Possible contributions of endogenous prostaglandins to the control of blood pressure. Circ Res 36–37 (Suppl 1): I-68–75Google Scholar
  145. 144.
    Verberckmös R, van Damme B, Clement J, Amery A, Michielsen P (1976) Bartter’s syndrome with hyperplasia of renomedullary cells: successful treatment with indomethacin. Kidney Int 9: 302–307CrossRefGoogle Scholar
  146. 145.
    Vinci JM, Telles DA, Bowden RE, Izzo IL, Keiser HR, Radfar N, Taylor AA, Gill JR, Bartter FC (1976) The kallikrein-kinin system (KKS) in Bartter’s syndrome (BS) and its response to prostaglandin synthetase inhibition ( PGSI ). Clin Res 24: 414AGoogle Scholar
  147. 146.
    Vinci J, Zusman R, Bowden R, Horowitz D, Keiser H (1977) Relationship of urinary and plasma kinins to sodium-retaining steroids and plasma renin activity. Clin Res 25: 450AGoogle Scholar
  148. 147.
    Vinci JM, Zusman RM, Izzo IL Jr, Bowden RE, Horowitz D, Pisano JJ, Keiser HR (1979) Human urinary and plasma kinins. Relationship to sodium-retaining steroids and plasma renin activity. Circ Res 44 (2): 228–237CrossRefPubMedGoogle Scholar
  149. 148.
    Ward PE, Gedney CD, Dowben RM, Erdös EG (1975) Isolation of membrane bound renal kallikrein and kininase. Biochem J 151: 755–758PubMedGoogle Scholar
  150. 149.
    Weber PC, Larsson C, Änggard E, Hamberg M, Corey EJ, Nicolaou KD, Samuelsson B (1976) Stimulation of renin release from rabbit renal cortex by arachidonic acid and prostaglandin endoperoxides. Circ Res 39: 868–874CrossRefGoogle Scholar
  151. 150.
    Weber PC, Larsson C, Scherer B (1977) Prostaglandin E2–9-ketoreductase as a mediator of salt intake-related prostaglandin-renin interactionGoogle Scholar
  152. 151.
    Weber PC, Scherer B, Larsson C (1977) Increase 280 J. M. Sullivan und J. C. McGiff of free arachidonic acid by furosemide in man as the cause of prostaglandin and renin release. Eur J Pharmacol 41: 329–332Google Scholar
  153. 152.
    Wennmalm Ä (1974) Hypertensive effect of the prostaglandin synthesis inhibitor indomethacin. IRCS (Research on: Endocrine System) 2: 1099Google Scholar
  154. 153.
    Whorton AR, Misono K, Hollifield J, Frölich JC, Inagami T, Oates JA (1977) Prostaglandins and renin release: Stimulation of renin release from rabbit renal cortical slices by PGI2. Prostaglandins 14: 1095–1104PubMedGoogle Scholar
  155. 154.
    Widimsky J, Fejfarova MD, Fejfar Z (1957) Changes of cardiac output in hypertensive disease. Cardiologia 31: 381–389CrossRefPubMedGoogle Scholar
  156. 155.
    Willis LR, Ludens JH, Hook JB, Williamson HE (1969) Mechanism of natriuretic action of bradykinin. Am J Physiol 217: 1–5PubMedGoogle Scholar
  157. 156.
    Wilson TW, Loadholt CB, Privitera PJ, Halushka PV (1982) Furosemide increases urine 6-ketoprostaglandin Fla. Relation to natriuresis, vaso-dilation, and renin release. Hypertension 4: 634–641Google Scholar
  158. 157.
    Wong PY, Talamo RC, Williams GH, Coleman RW (1975) Response of the kallikrein-kinin and renin-angiotensin systems to saline infusion and upright posture. J Clin Invest 55: 691–698CrossRefPubMedGoogle Scholar
  159. 158.
    Wong PY-K, Terragno DA, Terragno NA, McGiff JC (1977) Dual effects of bradykinin on prostaglandin metabolism: relationship to the dissimilar vascular actions of kinins. Prostaglandins 13: 1113–1125PubMedGoogle Scholar
  160. 159.
    Wong PY-K, Sun FF, McGiff JC (1978) Metabolism of prostacyclin in blood vessels. J Biol Chem 253: 5555–5557PubMedGoogle Scholar
  161. 160.
    Wong PY-K, Lee WH, Chao PH-W, Reiss RF, McGiff JC (1980) Metabolism of prostacyclin by 9-hydroxyprostaglandin dehydrogenase in human platelets. J Biol Chem 255: 9021–9024PubMedGoogle Scholar
  162. 161.
    Yarger WE, Griffith LD (1974) Intrarenal hemodynamics following chronic unilateral ureteral obstruction in the dog. Am J Physiol 227: 816–826PubMedGoogle Scholar
  163. 162.
    Yuan B, Tai CL, Tai HH (1980) 9-hydroxyprostaglandin dehydrogenase from rat kidney. J Biol Chem 255: 7439–7443Google Scholar
  164. 163.
    Yun J, Kelly G, Bartter FC (1979) Effect of indomethacin on renal function and plasma renin activity in dogs with chronic renovascular hypertension. Nephron 24: 278–282CrossRefPubMedGoogle Scholar
  165. 164.
    Zinner SH, Margolius HS, Rosner B, Keiser HR, Kass EH (1976) Familial aggregation of urinary kallikrein concentration in childhood: relation to blood pressure, race and urinary electrolytes. Am J Epidemol 104: 124–132Google Scholar
  166. 165.
    Zinner SH, Margolius HS, Rosner B, Kass EH (1977) Eight year longitudinal study of blood pressure and urinary kallikrein in childhood. Clin Res 25: 266AGoogle Scholar
  167. 166.
    Zusman RM, Keiser HR (1977) Prostaglandin biosynthesis by rabbit renomedullary interstitial cells in tissue culture. J Clin Invest 60: 215–223CrossRefPubMedGoogle Scholar
  168. 167.
    Zusman RM, Caldwell BV, Mulrow PJ, Speroff L (1973) The role of prostaglandin A in the control of sodium homeostasis and blood pressure. Prostaglandins 3: 679–690PubMedGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1984

Authors and Affiliations

  • J. M. Sullivan
  • J. C. McGiff

There are no affiliations available

Personalised recommendations